ONEOK Issues Annual Corporate Sustainability Report
Prnewswire· 2024-08-02 04:30
TULSA, Okla., Aug. 1, 2024 /PRNewswire/ -- ONEOK, Inc. (NYSE: OKE) today announced the release of its annual Corporate Sustainability Report highlighting the company's progress and commitment toward environmental, social and governance (ESG) performance. The report is available on ONEOK's website, www.oneok.com.Report Highlights:Achieved reductions equating to approximately 50% of ONEOK's total 2030 greenhouse gas emissions reduction target, as of year-end 2023.ONEOK reduced Scope 1 methane emissions 36% fr ...
The Pennant Group Announces New $250 Million Credit Facility
Newsfilter· 2024-08-02 04:21
EAGLE, Idaho, Aug. 01, 2024 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ:PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, today announced that the Company has increased its credit facility by $100 million to an aggregate of $250 million. The borrowings are supported by a lending consortium arranged by Truist Securities. The new facility expires on July 31, 2029. "This amended facility further strengthens our balance sheet, and together wit ...
CENTOGENE Publication in Brain Journal Reveals 15% of Parkinson's Disease Cases Are Linked to Genetic Factors
Newsfilter· 2024-08-02 04:15
Initial data from largest international Parkinson's disease patient cohort shows approximately 90% of these genetically confirmed patients had variants in the LRRK2 or GBA1 genes, making these individuals potential candidates to be included in gene-targeted trialsThe Rostock International Parkinson's Disease (ROPAD) Study aims to characterize the genetics of Parkinson's disease (PD) to establish a better understanding of disease progression, diagnosis, and treatment for patients CAMBRIDGE, Mass. and ROSTOCK ...
Occidental Completes Acquisition of CrownRock
Newsfilter· 2024-08-02 04:15
HOUSTON, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Occidental (NYSE:OXY) announced today that it has closed its acquisition of CrownRock, L.P. "By completing this transaction, Occidental adds assets that we believe make the best portfolio in our company's history even stronger and more differentiated. We also welcome new team members who will combine with ours to form a high-performing employee base that is focused on safely and efficiently developing low-emission, low-cost energy," said President and Chief Executi ...
Trupanion to Participate in the Canaccord Genuity 44th Annual Growth Conference
Newsfilter· 2024-08-02 04:15
SEATTLE, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Trupanion, Inc. (NASDAQ:TRUP) announced today that Margi Tooth, President and Chief Executive Officer, and Fawwad Qureshi, Chief Financial Officer, will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference in Boston, Massachusetts on Tuesday, August 13, 2024 at 12:30 p.m. ET and will participate in meetings with investors throughout the day. The presentation will be webcast live and can be accessed on Trupanion's Investor Relations ...
Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock
Newsfilter· 2024-08-02 04:10
VANCOUVER, British Columbia, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (NASDAQ:ZYME) (the "Company"), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that its Board of Directors has authorized a Share Repurchase Program under which the Company may repurchase up to $60.0 million of the Company's outstanding common stock, par value $0.00001 per share. Zymeworks ...
Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update
Newsfilter· 2024-08-02 04:10
– Petosemtamab in combination with pembrolizumab interim data presented at 2024 ASCO® demonstrated robust 67% response rate among 24 evaluable patients – First patients dosed in phase 3 trial evaluating petosemtamab monotherapy in 2/3L HNSCC, phase 2 trial evaluating petosemtamab in combination with standard chemotherapy in 2L mCRC, and phase 2 trial evaluating MCLA-129 in combination with chemotherapy in 2L+ EGFRm NSCLC – Based on the Company's current operating plan, existing cash, cash equivalents, inclu ...
SiriusPoint Announces Dividend on Series B Preference Shares
Newsfilter· 2024-08-02 04:10
HAMILTON, Bermuda, Aug. 01, 2024 (GLOBE NEWSWIRE) -- SiriusPoint Ltd. ("SiriusPoint" or the "Company") (NYSE:SPNT), an international specialty insurer and reinsurer, has announced that the Audit Committee of the Board of Directors of SiriusPoint Ltd. approved a quarterly cash dividend of $0.50 per share on its 8.00% Resettable Fixed Rate Preference Shares, Series B, $0.10 par value, $25.00 liquidation preference per share payable on August 30, 2024 to Series B shareholders of record as of August 15, 2024. A ...
Quoin Pharmaceuticals to Announce Second Quarter 2024 Financial Results on Thursday, August 8, 2024
Newsfilter· 2024-08-02 04:10
ASHBURN, Va., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its second quarter 2024 financial results before the market opens on Thursday, August 8, 2024. The announcement will provide an operational update regarding the company's achievements during the quarter and will detail financial highlights. About Quoin Pharm ...
Casella Waste Systems, Inc. Announces Second Quarter 2024 Results and Recent Acquisitions; Updates Fiscal Year 2024 Guidance
Newsfilter· 2024-08-02 04:10
RUTLAND, Vt., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Casella Waste Systems, Inc. (NASDAQ:CWST), a regional solid waste, recycling and resource management services company, today reported its financial results for the three and six-month periods ended June 30, 2024. Key Highlights: Revenues were $377.2 million for the quarter, up $87.5 million, or up 30.2%, from the same period in 2023.Solid waste pricing for the quarter was up 5.7% from the same period in 2023, driven by 6.2% collection price growth and 4.8% dis ...